Display options
Cite
Karam MC, Merckbawi R, Salman S, et al. Atenolol Reduces Leishmania major-Induced Hyperalgesia and TNF-α Without Affecting IL-1β or Keratinocyte Derived Chemokines (KC). Front Pharmacol. 2016;7:22doi: 10.3389/fphar.2016.00022.
Karam, M. C., Merckbawi, R., Salman, S., & Mobasheri, A. (2016). Atenolol Reduces Leishmania major-Induced Hyperalgesia and TNF-α Without Affecting IL-1β or Keratinocyte Derived Chemokines (KC). Frontiers in pharmacology, 722. https://doi.org/10.3389/fphar.2016.00022
Karam, Marc C, et al. "Atenolol Reduces Leishmania major-Induced Hyperalgesia and TNF-α Without Affecting IL-1β or Keratinocyte Derived Chemokines (KC)." Frontiers in pharmacology vol. 7 (2016): 22. doi: https://doi.org/10.3389/fphar.2016.00022
Karam MC, Merckbawi R, Salman S, Mobasheri A. Atenolol Reduces Leishmania major-Induced Hyperalgesia and TNF-α Without Affecting IL-1β or Keratinocyte Derived Chemokines (KC). Front Pharmacol. 2016 Feb 15;7:22. doi: 10.3389/fphar.2016.00022. eCollection 2016. PMID: 26913003; PMCID: PMC4753302.
Copy Download .nbib Format: NLM
Share it on

Front Pharmacol. 2016 Feb 15;7:22. doi: 10.3389/fphar.2016.00022. eCollection 2016.

Atenolol Reduces Leishmania major-Induced Hyperalgesia and TNF-α Without Affecting IL-1β or Keratinocyte Derived Chemokines (KC).

Frontiers in pharmacology

Marc C Karam, Rana Merckbawi, Sara Salman, Ali Mobasheri

Affiliations

  1. Department of Biology, University of Balamand Kourah, Lebanon.
  2. Department of Veterinary Preclinical Sciences, School of Veterinary Medicine, Faculty of Health and Medical Sciences, University of SurreyGuildford, UK; Center of Excellence in Genomic Medicine Research, King Fahd Medical Research Center, Faculty of Applied Medical Sciences, King Abdulaziz UniversityJeddah, Saudi Arabia.

PMID: 26913003 PMCID: PMC4753302 DOI: 10.3389/fphar.2016.00022

Abstract

Infection with a high dose of the intracellular parasitic protozoan Leishmania major induces a sustained hyperalgesia in susceptible BALB/c mice accompanied by up-regulation of the pro-inflammatory cytokines IL-1β and IL-6. Interleukin-13 (IL-13) has been shown to reduce this hyperalgesia (despite increased levels of IL-6) and the levels of IL-1β during and after the treatment period. These findings favor the cytokine cascade leading to the production of sympathetic amines (involving TNF-α and KC) over prostaglandins (involving IL-lβ and IL-6) as the final mediators of hyperalgesia. The aim of this study was to investigate the effect of daily treatment with the β-blockers atenolol on L. major-induced inflammation in mice with respect to hyperalgesia as well as the levels of TNF-α and KC (the analog of IL-8 in mice). Our data demonstrates that atenolol is able to reduce the L. major induced sustained peripheral hyperalgesia, which does not seem to involve a direct role for neither IL-lβ nor KC. Moreover, our results show that TNF-α may play a pivotal and direct role in sensitizing the peripheral nerve endings (nociceptors) since its level was reduced during the period of atenolol treatment, which correlates well with the reduction of the observed peripheral, but not central, hyperalgesia. These findings contribute to a better understanding of the cytokine cascade leading to hyperalgesia and may lead to the development of new and more efficient medications for many types of pain.

Keywords: Leishmania major; TNF-αlpha; atenolol; hyperalgesia; inflammation; prostanoids; sympathetic amines

References

  1. Pain. 1996 Aug;66(2-3):373-9 - PubMed
  2. Front Cell Infect Microbiol. 2012 Jun 12;2:83 - PubMed
  3. Br J Pharmacol. 1991 Nov;104(3):765-7 - PubMed
  4. Br J Anaesth. 2001 Jul;87(1):3-11 - PubMed
  5. J Neuroimmunol. 2007 Feb;183(1-2):43-9 - PubMed
  6. Br J Pharmacol. 2000 Dec;131(7):1317-24 - PubMed
  7. J Neuroimmunol. 2011 May;234(1-2):49-54 - PubMed
  8. Trends Parasitol. 2009 Aug;25(8):383-91 - PubMed
  9. Brain Res Rev. 2007 Nov;56(1):148-69 - PubMed
  10. Med Microbiol Immunol. 2001 Nov;190(1-2):73-6 - PubMed
  11. Br J Pharmacol. 1992 Nov;107(3):660-4 - PubMed
  12. Exp Mol Pathol. 2002 Apr;72(2):132-41 - PubMed
  13. Neuron. 2007 Aug 2;55(3):353-64 - PubMed
  14. Proc Natl Acad Sci U S A. 2005 Feb 1;102(5):1755-60 - PubMed
  15. Pharmacol Ther. 2006 Oct;112(1):116-38 - PubMed
  16. Pain. 2000 Apr;85(3):477-82 - PubMed
  17. J Oral Maxillofac Surg. 1994 Aug;52(8):786-91; discussion 791-2 - PubMed
  18. Exp Brain Res. 2009 Jun;196(1):129-37 - PubMed
  19. Br J Pharmacol. 1999 Feb;126(3):649-56 - PubMed
  20. Acta Neuropathol. 2003 Jun;105(6):593-602 - PubMed
  21. Exp Parasitol. 2006 Jul;113(3):168-73 - PubMed
  22. Infect Immun. 1992 Apr;60(4):1441-6 - PubMed
  23. Arthritis Rheum. 1997 Feb;40(2):217-25 - PubMed
  24. Pain. 1983 Jun;16(2):109-10 - PubMed
  25. Br J Pharmacol. 1993 Nov;110(3):1227-31 - PubMed
  26. Neuropharmacology. 2002 May;42(6):864-72 - PubMed
  27. Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2193-7 - PubMed

Publication Types